tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2021 Jun 22;1-10.
doi: 10.1080/21645515.2021.1932218. Online ahead of print.
Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis
Yu Liang[SUP] 1 [/SUP], Gao Jing-Xia[SUP] 1 [/SUP], Lei Ma[SUP] 1 [/SUP], Li Ni[SUP] 1 [/SUP], Ruan Chaolie[SUP] 1 [/SUP], Jian Zhou[SUP] 2 [/SUP], Liao Guo-Yang[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: The aim of the current study was to evaluate immunogenicity and safety levels of human inactivated quadrivalent influenza vaccine (QIV) which includes two A strains (A/H1N1, A/H3N2) and two B lineages (B/Victoria, B/Yamagata) in healthy adults via meta-analysis. Methods: Searches were conducted in PubMed, Cochrane Library, ClinicalTrials.gov, and EMBASE databases published in 2011-2020 according to inclusion and exclusion criteria. The purpose was to collect and perform meta-analysis of related randomized clinical trial (RCT) data concerning safety and immunogenicity levels of human QIV compared with inactivated trivalent influenza vaccine (TIV). Results: A total of 9 literatures were included. There was no significant difference in the seroconversion(SCR) and seroprotection(SPR) between QIV and TIV for influenza A strains (A/H1N1, A/H3N2) and the B lineage included in the TIV. QIV showed superior efficacy for the B lineage not included in the TIV: SCR RR of 2.20 (95%CI: 1.44-3.37, p = .0003) and SPR RR of 1.34 (95%CI: 1.10-1.63, p = .004) for B/Victoria, and SCR RR of 1.88 (95%CI: 1.53-2.31, p < .00001) and SPR RR of 1.11 (95%CI: 1.03-1.19, p = .006) for B/Yamagata, respectively. There were no significant differences between QIV and TIV for local and systemic adverse events(AE) post-vaccination. Conclusion: In adults 18-64 years old, QIV not only produced similar immunogenicity and safety levels to TIV, but also had better immunogenicity against influenza B vaccine strains not included in TIV.
Keywords: QIV; TIV; immunogenicity; meta-analysis; safety.
. 2021 Jun 22;1-10.
doi: 10.1080/21645515.2021.1932218. Online ahead of print.
Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis
Yu Liang[SUP] 1 [/SUP], Gao Jing-Xia[SUP] 1 [/SUP], Lei Ma[SUP] 1 [/SUP], Li Ni[SUP] 1 [/SUP], Ruan Chaolie[SUP] 1 [/SUP], Jian Zhou[SUP] 2 [/SUP], Liao Guo-Yang[SUP] 1 [/SUP]
Affiliations
- PMID: 34156322
- DOI: 10.1080/21645515.2021.1932218
Abstract
Objective: The aim of the current study was to evaluate immunogenicity and safety levels of human inactivated quadrivalent influenza vaccine (QIV) which includes two A strains (A/H1N1, A/H3N2) and two B lineages (B/Victoria, B/Yamagata) in healthy adults via meta-analysis. Methods: Searches were conducted in PubMed, Cochrane Library, ClinicalTrials.gov, and EMBASE databases published in 2011-2020 according to inclusion and exclusion criteria. The purpose was to collect and perform meta-analysis of related randomized clinical trial (RCT) data concerning safety and immunogenicity levels of human QIV compared with inactivated trivalent influenza vaccine (TIV). Results: A total of 9 literatures were included. There was no significant difference in the seroconversion(SCR) and seroprotection(SPR) between QIV and TIV for influenza A strains (A/H1N1, A/H3N2) and the B lineage included in the TIV. QIV showed superior efficacy for the B lineage not included in the TIV: SCR RR of 2.20 (95%CI: 1.44-3.37, p = .0003) and SPR RR of 1.34 (95%CI: 1.10-1.63, p = .004) for B/Victoria, and SCR RR of 1.88 (95%CI: 1.53-2.31, p < .00001) and SPR RR of 1.11 (95%CI: 1.03-1.19, p = .006) for B/Yamagata, respectively. There were no significant differences between QIV and TIV for local and systemic adverse events(AE) post-vaccination. Conclusion: In adults 18-64 years old, QIV not only produced similar immunogenicity and safety levels to TIV, but also had better immunogenicity against influenza B vaccine strains not included in TIV.
Keywords: QIV; TIV; immunogenicity; meta-analysis; safety.